Renal function and non-coronary atherosclerosis progression in patients with coronary artery disease one year after coronary artery bypass

Aim. To study associations of the estimated glomerular filtration rate (eGFR) with non-coronary atherosclerosis progression criteria and risk factors one year after coronary bypass surgery (CABG).

Material and methods. Of the 732 patients consecutively operated (586 men and 146 women, median age 59 years), 504 people visited the study center 1 year after CABG. At the preoperative and annual stages, all patients were assessed with the same set of clinical, instrumental and laboratory methods, and the ankle-brachial index (ABI) was measured. The eGFR was calculated by the CKD-EPI formula. Depending on the severity of non-cardiac arterial stenoses, the following groups were identified: <30%; 30-49%; 50-69%; 70-99%; occlusion; absence of stenosis. The criteria for the atherosclerosis progression was the presence of at least one of the following: the transition of stenosis from one group to another; decrease in initially normal ABI <0,9; decrease in ABI initially abnormal (<0,9) by more than 10%. For the analysis, two groups were identified: group 1 (n=375) without progression and group 2 (n=129) with progression of atherosclerosis.

Results. Preoperatively, the number of patients with eGFR <60 ml/min/1,73 m2 was equal in both groups. At both control points, eGFR was higher in 1 group (p=0,072 and 0,025, respectively). During the year, eGFR increased in both groups with significant differences among first one (p<0,001). One year after the operation, eGFR positively correlated with ABI (p=0,004) and with total and low-density lipoprotein cholesterol levels. Polyvascular disease determined from 30% of stenosis, was negatively associated with preoperative and annual eGFR (p=0,011 and p=0,004, respectively) and from 50% — with eGFR calculated one year after CABG (p=0,006).

Conclusion. In patients with progression of non-coronary atherosclerosis 1 year after CABG CKD-EPI eGFR was lower compared to patients without progression. In the long-term period the estimated values of renal function are significantly higher in patients without atherosclerosis progression.

1. Briasoulis A, Bakris GL. Chronic kidney disease as a coronary artery disease risk equivalent. Curr Cardiol Rep. 2013;3:340. doi:10.1007/s11886-012-0340-4.

2. Eisen A, Porter A, Hoshen M, et al. The association between eGFR in the normal or mildly impaired range and incident cadiovascular disease: Age and sex analysis. Eur J Intern Med. 2018 May 14. pii: S0953-6205(18)30192-4. doi:10.1016/j.ejim.2018.05.015.

3. McClellan WM, Newsome BB, McClure LA, et al. Chronic kidney disease is often unrecognized among patients with coronary heart disease: the REGARDS Cohort Study. Am J Nephrol. 2009;29:10-7.

4. Sud M, Tangri N, Pintilie M, et al. Risk of end-stage renal disease and death after cardiovascular events in chronic kidney disease. Circulation. 2014;130:458-65.

5. Sumin AN, Bezdenezhnykh NA, Bezdenezhnykh AV, et al. Risk factors of major cardiovascular events in long-term period of coronary bypass in patients with ischemic heart disease and 2nd type diabetes mellitus. Russian Journal of Cardiology. 2015;(6):30- 7. (In Russ.). doi:10.15829/1560-4071-2015-6-30-37.

6. Levey AS, Stevens LA. Estimating GFR Using the CKD Epidemiology Collaboration (CKDEPI) Creatinine Equation: More Accurate GFR Estimates, Lower CKD Prevalence Estimates, and Better Risk Predictions. Am J Kidney Dis. 2010 April;55(4):622-7. doi:10.1053/j.ajkd.2010.02.337.

7. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3:1-150.

8. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney International Supplements (2012). https://kdigo.org/clinical_practice_guidelines/pdf/KDIGO%20AKI%20Guideline.

9. Bezdenezhnykh AV, Sumin AN, Kazachek YV, et al. The risk factors and evaluation criteria for progression of atherosclerosis in one year post coronary bypass. Russian Journal of Cardiology. 2017;22(5):117-25 (In Russ.). doi:10.15829/1560-4071-2017-5-117-125.

10. Randrianarisoa E, Rietig R, Jacob S, et al. Normal values for intima-media thickness of the common carotid artery–an update following a novel risk factor profiling. Vasa. 2015 Nov;44(6):444-50. doi:10.1024/0301-1526/a000467.

11. Nishimura H, Miura T, Minamisawa M, et al. Ankle-brachial Index for the Prognosis of Cardiovascular Disease in Patients with Mild Renal Insufficiency. Intern Med. 2017 Aug 15;56(16):2103-11. doi:10.2169/internalmedicine.8215-16.

12. Nishimura H, Miura T, Minamisawa M, et al. Clinical Characteristics and Outcomes of Patients with High Ankle-Brachial Index from the IMPACT-ABI Study. PLoS ONE. 2016;11(11):e0167150. doi:10.1371/journal.pone.0167150.

13. Lim CC, Tan CS, Chia CM, et al. Long-Term Risk of Progressive Chronic Kidney Disease in Patients with Severe Acute Kidney Injury Requiring Dialysis after Coronary Artery Bypass Surgery. Cardiorenal Med. 2015 Jun;5(3):157-63. doi:10.1159/000381068.

14. Hassan MO, Duarte R, Dix-Peek T, et al. Volume overload and its risk factors in South African chronic kidney disease patients: an appraisal of bioimpedance spectroscopy and inferior vena cava measurements. Clin Nephrol. 2016 Jul;86(7):27-34. doi:10.5414/CN108778.

15. Luczak M, Formanowicz D, Marczak Ł, et al. Deeper insight into chronic kidney diseaserelated atherosclerosis: comparative proteomic studies of blood plasma using 2DE and mass spectrometry. J Transl Med. 2015 Jan 27;13:20. doi:10.1186/s12967-014-0378-8.

16. Hénaut L, Chillon JM, Kamel S, et al. Updates on the Mechanisms and the Care of Cardiovascular Calcification in Chronic Kidney Disease. Semin Nephrol. 2018 May;38(3):233-50. doi:10.1016/j.semnephrol.2018.02.004.

17. Kalantar-Zadeh K, Rhee CM, Chou J, et al. The Obesity Paradox in Kidney Disease: How to Reconcile it with Obesity Management. Kidney Int Rep. 2017 Mar;2(2):271-81. doi:10.1016/j.ekir.2017.01.009.

18. Grabulosa CC, Manfredi SR, Canziani ME, et al. Chronic kidney disease induces inflammation by increasing Toll-like receptor-4, cytokine and cathelicidin expression in neutrophils and monocytes. Exp Cell Res. 2018 Apr 15;365(2):157-62. doi:10.1016/j.yexcr.2018.02.022.

19. Sibal L, Agarwal SC, Home PD, et al. The Role of Asymmetric Dimethylarginine (ADMA) in Endothelial Dysfunction and Cardiovascular Disease. Curr Cardiol Rev. 2010 May; 6(2):82-90. doi:10.2174/157340310791162659.

20. Hyla-Klekot L, Bryniarski P, Pulcer B, et al. Dimethylarginines as risk markers of atherosclerosis and chronic kidney disease in children with nephrotic syndrome. Adv Clin Exp Med. 2015 Mar-Apr;24(2):307-14. doi:10.17219/acem/40465.

21. Sumin AN, Bezdenezhnykh NA, Bezdenezhnyh AV, et al. Peripheral atherosclerosis, diabetes and long-term results of coronary artery bypass grafting. Creative Cardiology. 2014;8(4):5-17 (In Russ.)

22. Gelsomino S, Del Pace S, Parise O, et al. Impact of renal function impairment assessed by CKDEPI estimated glomerular filtration rate on early and late outcomes after coronary artery bypass grafting. Int J Cardiol. 2017 Jan 15;227:778-87. doi:10.1016/j.ijcard.2016.10.059.